Pfiz­er adds shifts, in­vests re­sources to cope with surge in de­mand for syphilis treat­ment

As Pfiz­er con­tin­ues to grap­ple with in­creased de­mand for its an­tibi­ot­ic Bi­cillin, ex­perts wor­ry short­ages may stoke the wors­en­ing syphilis epi­dem­ic in the US. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER